Anti-IgE therapy to Kimura's disease: a pilot study

Area of Science:

• Immunology
• Dermatology
• Oncology

Background:

• Kimura's disease is a rare, chronic inflammatory condition affecting soft tissues in the head and neck.
• It is characterized by subcutaneous granulomas, elevated eosinophils, and high serum IgE levels, suggesting an IgE-mediated mechanism.
• Omalizumab, a monoclonal antibody targeting IgE, has demonstrated efficacy in other IgE-mediated diseases like asthma and allergic rhinitis.

Observation:

• Three patients with Kimura's disease were treated with eight cycles of subcutaneous omalizumab (300mg every 2 weeks).
• Tumor size was assessed via MRI, and peripheral blood eosinophil and basophil counts were monitored monthly.
• Treatment efficacy was evaluated at baseline and after four months.

Findings:

• All three patients experienced a reduction in the size of tumorous regions after omalizumab treatment.
• Peripheral blood eosinophil and basophil counts significantly decreased in all patients.
• The observed reductions suggest a positive response to anti-IgE therapy.

Implications:

• Omalizumab may represent a novel and effective systemic treatment option for Kimura's disease.
• Further research is warranted to confirm these findings and establish optimal treatment protocols.
• Targeting IgE with omalizumab could offer a new therapeutic avenue for patients with this challenging condition.